Cubist Systematic Strategies’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Cubist Systematic Strategies’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-150	Closed	-$67K	–	4667
2022 Q2	$67K	Sell	150 -86	-36%	-$60.8K	﹤0.01%	4047
2022 Q1	$292K	Sell	236 -246	-51%	-$335K	﹤0.01%	2857
2021 Q4	$1.22M	Buy	482 +433	+884%	+$2.64M	0.01%	1765
2021 Q3	$896K	Buy	49 +20	+69%	+$318K	0.01%	1613
2021 Q2	$302K	Hold	29	–	–	﹤0.01%	2325
2021 Q1	$211K	Sell	29 -89	-75%	-$640K	﹤0.01%	2436
2020 Q4	$657K	Buy	+118	New	+$1.05M	0.01%	1628

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Cubist Systematic Strategies's IRLA Position: Q3 2022 in Review

Cubist Systematic Strategies sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2022, closing a stake of 150 shares — an estimated $67K sold.

Cubist Systematic Strategies first reported a position in IRLA in Q4 2020 and held it in 7 quarters. The position peaked at $1.22M in Q4 2021. 58 funds tracked by Wall St. Rank hold IRLA as of Q3 2022.

Cubist Systematic Strategies reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Cubist Systematic Strategies sold 150 IRulya Therapeutics Inc. Common Stock shares in Q3 2022, an estimated $67K.
Cubist Systematic Strategies first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Cubist Systematic Strategies's IRulya Therapeutics Inc. Common Stock position peaked at $1.22M in Q4 2021.
58 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2022.

Based on Cubist Systematic Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.